Switched Memory B-cells as a Marker for Humoral Immune System Recovery in Patients With Secondary Antibody Deficiency Due to Hematological Malignancies

• Status: Not yet recruiting
• Trial end date: 2025-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Current treatment for patients with secondary antibody deficiency (SAD) is Immunoglobulin replacement therapy (IGRT). There are currently no clinical guidelines for IGRT discontinuation in patients with SAD. This study will examine the IGRT discontinuation success rate and IGRT discontinuation rate in patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ottawa Hospital Research Institute
• Treatments: Antibodies; Immunoglobulins; Immunoglobulins, Intravenous

Criteria

Inclusion Criteria:

1. History of leukemia, lymphoma, or plasma cell disease

2. Receiving IGRT for SAD for at least 12 months

3. Over 18 years of age

4. Able to provide informed consent

5. Able to speak English or French

6. Available for ongoing follow-up as required

Exclusion Criteria:

1. Receiving chemotherapy or immune-oncology treatment during the study period

2. Severe infection within the last 6 months

3. Pregnancy